Scott Nicholas Gettinger MD

Associate Professor Of Medicine (Medical Oncology)

Specialties & Subspecialties

Cancer Center, Yale: Thoracic Oncology Program

Internal Medicine: Medical Oncology

Education & Training

  • B.S., Trinity College (CT) (1991)
  • M.D., State University of New York At Brooklyn College (1999)
  • Resident, Beth Israel Medical Center, NY , Internal Medicine (1999 - 2002)
  • Fellow, Beth Israel Medical Center, NY , Medical Oncology and Hematology (2002 - 2005)

Patient Care

Accepts New Patients? Yes | Patient Type: Adult | Accepts referrals from patients


Clinical Interests

Lung cancer; mesothelioma; thymoma; head and neck cancer; thyroid cancer; mediastinal and chest wall tumors


Cancers Treated

Chest Wall Tumors, Lung, Mediastinal Tumors, Mesothelioma, Thymomas


Board Certifications

  • Hematology, Board Eligible
  • Medical Oncology, Board Certified (2005)

Clinical Trials

ConditionsStudy Title
Lung Cancer, Anus, Bladder, Bones and Joints, Brain and Nervous System, Breast - Female, Breast - Male, Cervix Uteri, Colon, Corpus Uteri, Esophagus, Eye and Orbit, Hodgkin's Lymphoma, Ill-Defined Sites, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Multiple Myeloma, Non-Hodgkin's Lymphoma, Other Digestive Organ, Other Endocrine System, Other Female Genital, Other Male Genital, Other Urinary, Ovary, Pancreas, Prostate, Rectum, Small Intestine, Soft Tissue, Stomach, and ThyroidA Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral ALK/EGFR Inhibitor AP26113
Breast Cancer (ER, PR, and HER2 negative), Colorectal Cancer, Endometrial Cancer, Gastric Adenocarcinoma, Glioblastoma Multiforme, Head/ Neck Squamous Cell Carcinoma, Melanoma, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Prostate Cancer, Brain and Nervous System, Breast - Female, Breast - Male, Colon, Lip, Oral Cavity and Pharynx, Lung, Melanoma, skin, Other Female Genital, Ovary, Prostate, Rectum, and StomachA Phase I/IIa, First Time in human, open-label dose-escalation study of GSK2636771 in subjects with advanced solid tumors with PTEN deficiency
LungA Phase 1b Open-label Study to Evaluate the Safety and Tolerability of MEDI4736 in Combination with Tremelimumab in Subjects With Advanced Non-Small Cell Lung Cancer
Bladder, Breast - Female, Lung, Pancreas, and StomachA Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors
Lung and Melanoma, skinA Phase 2 Study of MK-3475 in patients with metastatic melanoma and non-small cell lung cancer with untreated brain metastases

More Clinical Trials...

Edit Profile